CTRI/2011/12/002237已完成4 期
A Randomized, Open Label, Multicentre, Parallel-Group, Four Arm, Study Comparing Safety and Efficacy of Tacrolimus Topical Ointment (Bioconâ??s Formulation) Versus Protopic® Topical Ointment (Astellas Pharma) in Children and Adults with Atopic Dermatitis - Race
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 378
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male or female patients aged between 2 -75 years
- •Patients diagnosed with atopic dermatitis as per Hanifin and Rajka diagnostic standards
- •Patient/parents/guardian is capable of understanding the purposes and risks of the trial and has given written Informed Consent
- •Patient has documented evidence that they have been unresponsive to alternative traditional therapies such as topical corticosteroids, or in the investigators opinion, such first line therapy would be deemed inadvisable because of potential risks to the patient.
- •Patients with an IGA score of 3 (moderate) or 4 (severe) at the time of screening
- •Patients with Eczema Area and Severity Index (EASI) score of at least 15 at the time of screening
- •Treatment naive patients and/or patients receiving treatments for atopic dermatitis other than tacrolimus can be included in the study after 3 days of wash out period
- •Female patients of child bearing potential, using double barrier method or use a reliable method of contraception during the study
排除标准
- •Patient has clinically infected atopic dermatitis at baseline
- •Patient with known hypersensitivity to macrolides in general, to tacrolimus or any excipients of the ointment
- •Any dermatological condition other than atopic dermatitis that in the Investigators opinion may interfere with the evaluation of the patients atopic dermatitis
- •Patients using non-sedating anti-histamines 7 days prior to the first dosing day or at any point during the study
- •Current diagnosis or history or any disease, which in the Investigators opinion would contraindicate the use of immunosuppressantâ??s, including but not limited to human immunodeficiency virus (HIV) and cancer.
- •Females who are pregnant, lactating or likely to become pregnant during the study
研究者
相似试验
进行中(未招募)
不适用
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisEUCTR2009-015556-15-SIBiogen Idec Limited76
进行中(未招募)
1 期
Tezepelumab Home Use StudyEUCTR2018-004588-30-PLAstraZeneca AB210
进行中(未招募)
不适用
A Multicenter, Randomized, Open-Label, Parallel-Group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic Syndromes (MDS)The myelodysplastic syndromes (MDS) are a group of potentially acute myeloid leukemic disorders. The disorders of myeloid origin include acute myeloid leukemia (AML), MDS and myeloproliferative disorders such as chronic myeloid leukemia.MedDRA version: 6.1Level: PTClassification code 10028533EUCTR2004-001507-35-HUPharmion Corporation354
进行中(未招募)
1 期
To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid ArthritisMedDRA version: 18.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2012-004339-21-PLsanofi-aventis Recherche & Développement200
进行中(未招募)
不适用
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisEUCTR2009-015556-15-CZBiogen Idec Limited76
